VOLPE, SARA
 Distribuzione geografica
Continente #
NA - Nord America 60
EU - Europa 26
AS - Asia 10
Totale 96
Nazione #
US - Stati Uniti d'America 60
SE - Svezia 9
SG - Singapore 8
IT - Italia 7
DE - Germania 4
GB - Regno Unito 3
CN - Cina 2
FR - Francia 2
CZ - Repubblica Ceca 1
Totale 96
Città #
Chandler 14
Nyköping 9
Singapore 7
Cambridge 5
Ashburn 4
Bari 4
Fairfield 4
Munich 4
Seattle 3
Woodbridge 3
Beijing 2
New York 2
Ann Arbor 1
Council Bluffs 1
Des Moines 1
Inglewood 1
London 1
Olomouc 1
Paris 1
Redwood City 1
Romola 1
Roxbury 1
Santa Clara 1
Southwark 1
Tiverton 1
Wilmington 1
Totale 75
Nome #
Heat SHOCK proteins in equine spermatozoa: Expression and correlation to kinetic and environmental parameters 42
ANNUAL PROFILE OF HEAT SHOCK PROTEINS EXPRESSION IN EQUINE SPERMATOZOA AND ITS RELATIONSHIP WITH SEMINAL PARAMETERS 17
Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study 16
Effectiveness and clinical benefits of new anti-diabetic drugs: A real life experience 16
When Serum C-Peptide Measurement Drives Adequate Diabetes Mellitus Diagnosis and Therapy: A Case Report 8
Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study 7
Semaglutide Modulates Extracellular Matrix Production of LX-2 Cells via Exosomes and Improves Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) 6
When Inappropriate Use of Insulin is Dangerous: The Utility of C-Peptide Assay in the Era of Cardioprotective Antidiabetic Drugs 6
Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study 5
Totale 123
Categoria #
all - tutte 1.027
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.027


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202 0 0 0 0 0 0 0 0 0 2 0 0
2020/202123 0 0 5 1 2 7 0 5 1 2 0 0
2021/202211 1 0 0 0 1 0 0 1 1 0 3 4
2022/202333 0 3 2 1 4 9 1 4 7 1 1 0
2023/202430 4 0 1 1 2 3 7 3 5 2 1 1
2024/202523 12 1 10 0 0 0 0 0 0 0 0 0
Totale 123